| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7192938 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(4 months ago) | |
| US7718634 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(4 months ago) | |
|
US7192938 (Pediatric) | APIL | Method of treatment using bisphosphonic acid |
Nov, 2023
(a month from now) | |
|
US7718634 (Pediatric) | APIL | Method of treatment using bisphosphonic acid |
Nov, 2023
(a month from now) | |
Actonel is owned by Apil.
Actonel contains Risedronate Sodium.
Actonel has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Actonel are:
- US7192938
- US7718634
Actonel was authorised for market use on 27 March, 1998.
Actonel is available in tablet;oral dosage forms.
Actonel can be used as prevention and treatment of osteoporosis, treatment of osteoporosis in postmenopausal women.
The generics of Actonel are possible to be released after 06 November, 2023.
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 27 March, 1998
Treatment: Prevention and treatment of osteoporosis; Treatment of osteoporosis in postmenopausal women
Dosage: TABLET;ORAL
ACTONEL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic